Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
24 oct. 2022 16h30 HE
|
Mereo BioPharma Group plc
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
21 oct. 2022 07h00 HE
|
Mereo BioPharma Group plc
Reiterates Quality and Composition of Mereo’s Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo’s Strategy and Maximize Shareholder Value Details Rubric’s...
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
18 oct. 2022 07h00 HE
|
Mereo BioPharma Group plc
Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones Reiterates Commitment to Disciplined...
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
17 oct. 2022 07h00 HE
|
Mereo BioPharma Group plc
Designation Validates Alvelestat’s Potential to Address a Serious Unmet Need Company Plans R&D Update on Alvelestat in AATD-associated Lung Disease on October 31, 2022 LONDON, Oct. 17, 2022 ...
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
03 oct. 2022 17h00 HE
|
Mereo BioPharma Group plc
Rubric has Rejected Mereo’s Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo’s Board Mereo Reiterates Support for its Experienced,...
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board
26 sept. 2022 07h00 HE
|
Mereo BioPharma Group plc
Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer Rubric’s Second General Meeting Requisition Notice Again Fails to Satisfy Basic Requirements of the Companies Act 2006...
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors
12 sept. 2022 08h00 HE
|
Mereo BioPharma Group plc
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy Continued clinical benefit observed with the combination of...
Mereo BioPharma Sends Letter to Rubric Capital Management
31 août 2022 07h00 HE
|
Mereo BioPharma Group plc
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions Announces Further Extension of Cash Runway into Q2 2025 LONDON, Aug. 31,...
Mereo BioPharma Sends Letter to Rubric Capital Management
22 août 2022 04h00 HE
|
Mereo BioPharma Group plc
LONDON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology,...
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
05 juil. 2022 16h01 HE
|
Mereo BioPharma Group plc
LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare...